Vaccine Therapy in Treating Patients With Stage III-IV or Recurrent Ovarian Cancer

Inclusion Criteria: * Patients with advanced stage (III/IV) or recurrent ovarian cancer who have been treated to complete remission with standard therapies including primary debulking surgery * Cancer antigen 125 (CA-125) level within normal limits for the testing laboratory must be documented 90 days prior to enrollment when the assessment of CA-125 is applicable * Patients must be at least 28 days post cytotoxic chemotherapy, and/or monoclonal antibody therapy, prior to enrollment * Patients must be at least 28 days post systemic steroids prior to enrollment * Patients must have Eastern Cooperative Oncology Group (ECOG) Performance Status Score of =\< 2 * Patients must have recovered from major infections and/or surgical procedures, and in the opinion of the investigator, not have any significant active concurrent medical illnesses precluding protocol treatment * Estimated life expectancy of more than 6 months * White Blood Cell (WBC) \>= 3000/mm\^3 * Hemoglobin (Hgb) \>= 10 mg/dl * Hematocrit (Hct) \>= 28% * Serum creatinine =\< 2.0 mg/dl or creatinine clearance \> 60 ml/min * Total bilirubin =\< 2.5 mg/dl * Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) =\< 3 times upper limit of normal (ULN) * Blood glucose \< 1.5 ULN Exclusion Criteria: * Patients with any of the following cardiac conditions: symptomatic restrictive cardiomyopathy; unstable angina within 4 months prior to enrollment; New York Heart Association functional class III-IV heart failure on active treatment; symptomatic pericardial effusion * Uncontrolled diabetes * Patients with any contraindication to receiving sargramostim (rhuGM-CSF) based products * Ovarian cancer of a low malignant potential phenotype or clear cell histology * Patients with any clinically significant autoimmune disease uncontrolled with treatment * Patients who are currently receiving an anti-IGF-IR monoclonal antibody as part of their treatment regimen * Patients who are simultaneously enrolled in any other treatment study * All subjects able to bear children